Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA)

被引：0
|
作者：
Llibre, J. M. [1 ]
Alves, C. [2 ]
Cheng, C-Y [3 ,4 ]
Osiyemi, O. [5 ]
Galera, C. [6 ]
Hocqueloux, L. [7 ]
Maggiolo, F. [8 ]
Degen, O. [9 ]
Blair, E. [10 ]
Wynne, B. [10 ]
Oyee, J. [11 ]
Underwood, M. [10 ]
Curtis, L. [11 ]
Bontempo, G. [10 ]
van Wyk, J. [12 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[2] Univ Fed Bahia, Salvador, BA, Brazil
[3] Minist Hlth & Welf, Taoyuan Gen Hosp, Taoyuan, Taiwan
[4] Natl Yang Ming Univ, Sch Publ Hlth, Taipei, Taiwan
[5] Triple O Res Inst PA, W Palm Beach, FL USA
[6] Hosp Clin Univ Virgen de la Arrixaca, Murcia, Spain
[7] Ctr Hosp Reg Orleans, Orleans, France
[8] ASST Papa Giovanni XXIII, Bergamo, Italy
[9] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[10] ViiV Healthcare, Res Triangle Pk, NC USA
[11] GlaxoSmithKline, Uxbridge, Middx, England
[12] ViiV Healthcare, Brentford, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OALB0303
引用
收藏
页码：13 / 14
页数：2
相关论文
共 29 条
  • [21] Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection-48-week results from the GEMINI studies
    Cahn, P.
    Sierra Madero, J.
    Arribas, J.
    Antinori, A.
    Ortiz, R.
    Clarke, A.
    Hung, C. -C.
    Rockstroh, J.
    Girard, P. -M.
    Man, C.
    Sievers, J.
    Currie, A.
    Underwood, M.
    Tenorio, A.
    Pappa, K.
    Wynne, B.
    Gartland, M.
    Aboud, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 156 - 156
  • [22] Systematic literature review of real-world experience with the 2-drug regimen dolutegravir plus lamivudine (DTG+3TC) in people with HIV-1 (PWH) aged ≥50 years
    Letang, E.
    Di Giambenedetto, S.
    Monforte, A. d'Arminio
    Casado, J.
    Cabello-Ubeda, A.
    Hocqueloux, L.
    Allavena, C.
    Barber, T. J.
    Kabra, M.
    Priest, J.
    Clark, A.
    Jones, B.
    HIV MEDICINE, 2023, 24 : 135 - 137
  • [23] Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASO-DOBLE (GeSIDA 11720) randomized clinical trial
    Ryan, P.
    Blanco, J. L.
    Masia, M.
    Garcia-Fraile, L.
    Crusells, M. J.
    Domingo, P.
    Curran, A.
    Guerri-Fernandez, R.
    Bernal, E.
    Bravo, J.
    Revollo, B.
    Macias, J.
    Tiraboschi, J. M.
    Montejano, R.
    Amador, C.
    Torralba, M.
    Merino, D.
    Diaz-Brito, V.
    Galindo, M. J.
    Ferra, S.
    Villoslada, A.
    Losa, J. E.
    Fanjul, F. J.
    Perez-Stachowski, J.
    Peraire, J.
    Portilla, J.
    de la Fuente, S.
    Duenas, C.
    Vazquez, M. J.
    Di Gregorio, S.
    Manzanares, E.
    Gil, P.
    de Miguel, M.
    Alejos, B.
    Martinez, E.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 90 - 91
  • [24] Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive women with HIV-1 infection (ARIA study): subgroup analyses
    Johnson, Margaret
    Gatey, Caroline
    Manosuthi, Weeraweet
    Lazzarin, Adriano
    Podzamczer, Daniel
    Man, Choy
    Aylott, Alicia
    Buchanan, Annie
    Wynne, Brian
    Vavro, Cindy
    Aboud, Michael
    Smith, Kim
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [25] CARAVEL: Evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination (FDC) in treatment-naive adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results
    Philibert, P.
    Charpentier, C.
    Naguleswaran, N.
    Philippe, C.
    Roustand, L.
    Vouillot, C.
    Hocqueloux, L.
    HIV MEDICINE, 2023, 24 : 71 - 72
  • [26] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
    Osiyemi, Olayemi
    De Wit, Stephane
    Ajana, Faiza
    Bisshop, Fiona
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Leone, Peter
    Pappa, Keith A.
    Wang, Ruolan
    Wright, Jonathan
    George, Nisha
    Wynne, Brian
    Aboud, Michael
    van Wyk, Jean
    Smith, Kimberly Y.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (06) : 975 - 986
  • [27] Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3))
    Johnson, VA
    Wagner, SF
    Overbay, CB
    Wagner, JR
    Cammack, N
    Penn, CR
    Rubin, M
    Bartlett, JA
    Fallon, MA
    Quinn, JB
    Benoit, SL
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 55 - 55
  • [28] CARAVEL: evaluation of real-world effectiveness and sustainability of the two-drug regimen dolutegravir/lamivudine fixed-dose combination in treatment-naive adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France: 2-year interim analysis results
    Philibert, Patrick
    Charpentier, Charlotte
    Naguleswaran, Nilakshani
    Philippe, Caroline
    Roustand, Laetitia
    Vouillot, Corinne
    Hocqueloux, Laurent
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 93 - 93
  • [29] D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
    Turkova, Anna
    Chan, Man K.
    Kityo, Cissy
    Kekitiinwa, Adeodata R.
    Musoke, Philippa
    Violari, Avy
    Variava, Ebrahim
    Archary, Moherndran
    Cressey, Tim R.
    Chalermpantmetagul, Suwalai
    Sawasdichai, Kanokkorn
    Ounchanum, Pradthana
    Kanjanavanit, Suparat
    Srirojana, Sakulrat
    Srirompotong, Ussanee
    Welch, Steven
    Bamford, Alasdair
    Epalza, Cristina
    Fortuny, Claudia
    Colbers, Angela
    Nastouli, Eleni
    Walker, Simon
    Carr, Dan
    Conway, Magda
    Spyer, Moira J.
    Parkar, Nazia
    White, Iona
    Nardone, Alessandra
    Thomason, Margaret J.
    Ferrand, Rashida A.
    Giaquinto, Carlo
    Ford, Deborah
    CONTEMPORARY CLINICAL TRIALS, 2024, 142
123